Clinical Trial

Good news leads to spike

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular carcinoma (HCC) who had not responded to first-line treatment with kinase inhibitor Nexavar. In the study, resmino­stat was administered alone and in combination with Nexavar. In 24 evaluable patients, the treatments led to progression-free survival of 33.3% (resminostat alone) and 66.6% (combination therapy) after 12 weeks. Resminostat is an oral pan-histone deacetylase (HDAC) inhibitor. 4SC said it plans to consult regulatory authorities in the US and EU on advice for a pivotal trial with the substance. Last September, resminostat met the primary endpoint of overall response rate in a Phase II SAPHIRE trial to treat Hodgkin’s lymphoma. The drug was originally invented by German pharma Altana AG, which was acquired by Nycomed. 4SC used the windfall to buy assets left over following the restructuring of Altana’s former oncology portfolio.

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Politics / Law

24.02.2012

London – The European Medicines Agency (EMA) will publish information about all drugs under review, beginning on March 1. On a monthly basis the company will issue a list disclosing the international non-proprietary name and...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/good-news-leads-to-spike.html

Product of the week

Products

Events

All Events

Current issue

All issues